Home / Therapeutic Area / Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

Published: May 2015 | Published By: GBI Research
GBI Research, the leading business intelligence provider, has released its latest research: ‘Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth’, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.
 
In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $435m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $773m. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant market share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.
 
Scope
 
The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.
 
The report includes:
 
  • A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms
  • In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy
  • A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type
  • Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006
 
Reasons To Buy
 
The report will enhance your decision-making capability by allowing you to:
 
  • Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative
  • Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in psoriasis clinical trial size and duration in relation to industry averages
  • Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates
  • Analyze the potential growth patterns expected for the psoriasis market over the forecast period
  • Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships
Table of Contents
 
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
 
2 Introduction 10
2.1 Symptoms 11
2.1.1 Skin Manifestations 11
2.1.2 Psychological Impact 11
2.2 Etiology, Co-morbidities and Risk Factors 11
2.2.1 Genetics 11
2.2.2 Psoriatic Arthritis 11
2.2.3 Mental Health Disorders 11
2.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 12
2.2.5 Infections 12
2.2.6 Köebner Phenomenon 12
2.2.7 Other Immune-Mediated Diseases 13
2.3 Pathophysiology 13
2.4 Diagnosis 13
2.5 Epidemiology 14
2.6 Treatment and Management 15
2.6.1 Pharmacological Therapies 16
2.6.2 Non-pharmacological Therapies 17
2.6.3 Combination and Rotational Therapies 18
2.6.4 Quality of Life Assessments 18
2.6.5 Summary 18
 
3 Marketed Products 19
3.1 Overview 19
3.2 Methotrexate-Based Products 19
3.3 Sandimmune/Neoral (cyclosporine/modified cyclosporin) – Novartis 20
3.4 Humira (adalimumab) – AbbVie 21
3.5 Enbrel (etanercept) – Amgen 23
3.6 Remicade (infliximab) – Janssen Biotech 25
3.7 Stelara (ustekinumab) – Janssen Biotech 26
3.8 Comparative Efficacy and Safety 28
 
4 Psoriasis Market to 2021 – Pipeline Products 30
4.1 Overview 30
4.2 Overall Pipeline 30
4.3 Pipeline Analysis by Molecule Type 32
4.4 Pipeline Analysis by Molecular Target 33
4.5 Clinical Trials 35
4.5.1 Overall Failure Rate 35
4.5.2 Failure Rate by Molecule Type 36
4.5.3 Failure Rate by Molecular Target 37
4.5.4 Patient Enrollment and Clinical Trial Size 38
4.5.5 Duration 39
4.5.6 Summary of Psoriasis Clinical Trials 40
4.6 Promising Drug Candidates in the Pipeline 41
4.6.1 LY2439821 (ixekizumab) – Eli Lilly 41
4.6.2 Xeljanz (tofacitinib) – Pfizer 42
4.6.3 Brodalumab – Amgen 43
 
5 Market Forecast to 2021 45
5.1 Geographical Markets 45
5.1.1 Asia-Pacific Market Overview 45
5.1.2 China 47
5.1.3 India 48
5.1.4 Japan 50
5.1.5 Australia 51
5.2 Drivers and Barriers 53
5.2.1 Drivers 53
5.2.2 Barriers 53
 
6 Deals and Strategic Consolidations 55
6.1 Major Co-development Deals 55
6.1.1 AbbVie Enters into Co-development Agreement with Biotest for Tregalizumab 59
6.1.2 Lycera Enters into Research Agreement with Merck 59
6.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases 60
6.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab 60
6.2 Major Licensing Deals 61
6.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug 64
6.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy's Laboratories 64
6.2.3 Cipher Pharmaceuticals Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch 64
6.2.4 Phenex Pharmaceuticals Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 65
 
7 Appendix 66
7.1 All Pipeline Drugs by Phase 66
7.1.1 Discovery 66
7.1.2 Preclinical 68
7.1.3 IND/CTA-Filed 71
7.1.4 Phase I 72
7.1.5 Phase II 75
7.1.6 Phase III 79
7.1.7 Pre-registration 80
7.2 Market Forecasts to 2021 80
7.2.1 Global 80
7.2.2 China 80
7.2.3 India 81
7.2.4 Japan 81
7.2.5 Australia 81
7.3 Market Definitions 82
7.4 Abbreviations 82
7.5 References 83
7.6 Research Methodology 87
7.6.1 Coverage 88
7.6.2 Secondary Research 88
7.6.3 Primary Research 88
7.6.4 Therapeutic Landscape 89
7.6.5 Geographical Landscape 91
7.6.6 Pipeline Analysis 92
7.7 Expert Panel Validation 92
7.8 Contact Us 92
7.9 Disclaimer 92
Table 1: Psoriasis Market, Global, Types of Psoriasis, 2015 10
Table 2: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Discovery, 2014 66
Table 3: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 68
Table 4: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 71
Table 5: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 72
Table 6: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 75
Table 7: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 79
Table 8: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 80
Table 9: Psoriasis Market, Asia-Pacific, Forecast Data, 2014–2021 80
Table 10: Psoriasis Market, China, Forecast Data, 2014–2021 80
Table 11: Psoriasis Market, India, Forecast Data, 2014–2021 81
Table 12: Psoriasis Market, Japan, Forecast Data, 2014–2021 81
Table 13: Psoriasis Market, Australia, Forecast Data, 2014–2021 81
Figure 1: Psoriasis Market, Global, Composite Treatment Algorithm, 2015 16
Figure 2: Psoriasis Market, Global, Humira (adalimumab), Annual Sales ($bn), 2007–2014 23
Figure 3: Psoriasis Market, Global, Enbrel (etanercept), Annual Sales ($bn), 2007–2014 24
Figure 4: Psoriasis Market, Global, Remicade (infliximab), Annual Sales ($bn), 2007–2014 26
Figure 5: Psoriasis Market, Global, Stelara (ustekinumab), Annual Sales ($bn), 2010–2014 27
Figure 6: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (1/2), 2015 28
Figure 7: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (2/2), 2015 29
Figure 8: Psoriasis Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2015 31
Figure 9: Psoriasis Market, Global, Pipeline by Molecule Type and Stage of Development, 2015 32
Figure 10: Psoriasis Market, Global, Pipeline by Molecular Target (1/2), 2015 33
Figure 11: Psoriasis Market, Global, Pipeline by Molecular Target (2/2), 2015 34
Figure 12: Psoriasis Market, Global, Pipeline by Molecular Target, Molecule Type and Stage of Development, 2015 35
Figure 13: Psoriasis Market, Global, Clinical Trial Failure Rate (%), 2015 36
Figure 14: Psoriasis Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2015 37
Figure 15: Psoriasis Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2015 38
Figure 16: Psoriasis Market, Global, Clinical Trial Size, 2015 39
Figure 17: Psoriasis Market, Global, Clinical Trial Duration (months), 2015 40
Figure 18: Psoriasis Market, Asia-Pacific, Treatment Use Patterns and Market Size ($m), 2014–2021 46
Figure 19: Psoriasis Market, China, Treatment Use Patterns, Annual Cost of Therapy ($) and Market Size ($m), 2014–2021 48
Figure 20: Psoriasis Diabetes Market, India, Treatment Use Patterns, Annual Cost of Therapy ($), and Market Size ($m), 2014–2021 49
Figure 21: Psoriasis Market, Japan, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size ($m), 2014–2021 51
Figure 22: Psoriasis Market, Australia, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size ($m), 2014–2021 52
Figure 23: Psoriasis Market, Global, Co-development Deals by Geography, Deals by Value, 2006–2014 56
Figure 24: Psoriasis Market, Global, Co-development Deals by Year, Deals by Phase and Molecule Type, 2006–2014 57
Figure 25: Psoriasis Market, Global, Co-development Deals by Molecule Type and Deal Value, Deals by Molecular Target and Deal Value, 2006–2014 58
Figure 26: Psoriasis Market, Global, Co-development Deals by Geography, 2006–2014 59
Figure 27: Psoriasis Market, Global, Licensing Deals by Geography and Value, 2006–2014 61
Figure 28: Psoriasis Market, Global, Licensing Deals by Year, Licensing Deals by Phase and Molecule Type, 2006–2014 62
Figure 29: Psoriasis Market, Global, Licensing Deals by Year and by Phase, 2006–2014 63
Figure 30: Psoriasis Market, Global, Licensing Deals by Geography, 2006–2014 64
Figure 31: GBI Research Market Forecasting Model (Example) 91
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +